About bsbh

This author has not yet filled in any details.
So far bsbh has created 194 blog entries.

IMI 1 GetReal closing meeting-Speakers

IMI 1 GetReal closing meeting: ‘Delivering tools for real-world evidence development’ 24 November, 2016, Brussels Royal Flemish Academy of Belgium for Science and the Arts Speakers Lucien Abenhaim, MD, PhD & Chairman, LASER Analytica Francesca Cerreta, Senior Scientific Officer, EMA Chris Chinn, Head of [...]

IMI 1 GetReal closing meeting-Speakers2018-03-05T18:12:38+00:00

Real world big data for clinical research and drug development

30th December, 2017



The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.

Real world big data for clinical research and drug development2018-04-24T13:18:20+00:00

Advanced Therapies – Opportunities and Challenges – Report

Advanced Therapies – Opportunities and Challenges 14th November, London Presentations Click on the name of the speaker to download the slide deck Keynote Session: “The Future of Advanced Therapies” Peter Goodfellow, Scientific Advisor, Abingworth “Regenerating the Future, Again” Lord James O’Shaughnessy, [...]

Advanced Therapies – Opportunities and Challenges – Report2017-11-16T14:12:59+00:00

Advanced Therapies – Opportunities and Challenges – Presentations

Organised in partnership with: Advanced Therapies – Opportunities and Challenges 14th November, London Presentations Click on the name of the speaker to download the slide deck Keynote Session: “The Future of Advanced Therapies” Peter Goodfellow, [...]

Advanced Therapies – Opportunities and Challenges – Presentations2017-11-30T11:28:48+00:00

Michaël Hocquemiller

Michaël Hocquemiller, PhD Scientific Director, Lysogene   Michaël Hocquemiller is scientific director at Lysogene. He has 10 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and [...]

Michaël Hocquemiller2017-11-13T09:11:29+00:00

Samantha Parker

Samantha Parker Chief Patient Officer Lysogene   Samantha Parker is Chief Patient Officer at Lysogene, with more than 20 years’ experience in the pharmaceutical industry: executive and management, strategic leadership, vice president of a foundation for independent professional education in rare diseases, global drug development & patient access across several rare disease [...]

Samantha Parker2017-10-25T13:51:57+00:00

Gabriele Proetzel

Gabriele Proetzel, Ph.D. Director, Regenerative Medicine, Takeda Gabriele Proetzel, PhD is Director of Regenerative Medicine at Takeda Pharmaceuticals, based in Cambridge, MA. In her current role she is focused on cell and gene therapy therapeutic approaches and strategic alliance management. Prior industry appointments were Chief Scientific Officer at Scil Proteins, Halle Germany, [...]

Gabriele Proetzel2017-10-12T07:10:48+00:00

Christian Schneider

Dr Christian K Schneider Director of National Institute for Biological Standards and Control (NIBSC) Dr Christian Schneider joined the National Institute for Biological Standards and Control (NIBSC) in January 2016, taking over as Director in April 2016. NIBSC is a centre of the Medicines and Healthcare products Regulatory Agency (MHRA). Christian is [...]

Christian Schneider2017-10-11T15:12:58+00:00

Lord James O’Shaughnessy

Lord James O'Shaughnessy Parliamentary Under Secretary of State for Health (Lords), UK Government   Lord O’Shaughnessy was appointed as a Parliamentary Under Secretary of State at the Department of Health and a Government Whip (Lord in Waiting) in December 2016. Lord O’Shaughnessy was a senior fellow at the Legatum Institute and at [...]

Lord James O’Shaughnessy2017-10-11T11:11:06+00:00